<DOC>
	<DOC>NCT01314079</DOC>
	<brief_summary>This is an open follow-up clinical trials to evaluate a sustained efficacy and safety of Adipoplus inj. for 10 months (12 months after final dose injection)after Phase II clinical trial.</brief_summary>
	<brief_title>Follow-up Study of Autologous Cultured Adipose-derived Stem Cells for the Crohn's Fistula</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<criteria>the patients who have participated in ANTGASC202 clinical trial the patients who have experienced with Adipoplus in ANTGASC202 trials the patients who submit written consents and is able to obey requirements of trials pregnant or breast feeding autoimmune disease other than Crohn's disease infectious diseases including HBV, HCV or HIV who is not willing to use effective contraceptive methods during the study. active tuberculosis moderate to severe active or worsened Crohn's disease who have received Infliximab during or after ANTGASC202 trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Crohn's fistula</keyword>
	<keyword>Autologous adipose derived stem cell</keyword>
</DOC>